CD70-targeted CAR-NKT Cells Therapy (CureGenetics)

N/A

Report date: 2024/05/20 16:11:07

Base Information

Drug NameCD70-targeted CAR-NKT Cells Therapy (CureGenetics)
Drug Alias NameCGC-729CGC729
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionNKT cells modulatorsCD70 antigen modulators
TargetsCD70 antigen
Therapy Area/IndicationsSolid tumoursCarcinoma, Renal Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSuzhou Cure Genetics Biosciences Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSuzhou Cure Genetics Biosciences Co LtdFudan University
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Renal Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A